Peri-interventional endothelin-A receptor blockade improves longterm outcome in patients with ST-elevation acute myocardial infarction

Thrombosis and Haemostasis

Volumn 112, Issue 1, 2014, Pages 176-182

  Adlbrecht, Christopher ^a   Wurm, Raphael ^a   Humenberger, Michael ^a   Andreas, Martin ^a   Redwan, Bassam ^a   Distelmaier, Klaus ^a   Klappacher, Günter ^a   Lang, Irene M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute myocardial infarction; BQ 123; Clinical outcome; Endothelin; Percutaneous coronary intervention; Remodelling

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYCLO (DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GELATINASE B; MINERALOCORTICOID ANTAGONIST; MYELOPEROXIDASE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PEROXIDASE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FUNDING; HOSPITALIZATION; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TELEPHONE INTERVIEW; CONTROLLED STUDY; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; NEUTROPHIL; PERIOPERATIVE PERIOD; PHYSIOLOGY; SURVIVAL; TREATMENT OUTCOME;

AGED; ENDOTHELIN RECEPTOR ANTAGONISTS; EXTRACELLULAR MATRIX; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUTROPHIL ACTIVATION; NEUTROPHILS; PEPTIDES, CYCLIC; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PEROXIDASE; RECEPTOR, ENDOTHELIN A; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84903791961     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0832     Document Type: Article

References (50)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol 1999; 126: 391-398.
3. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-876.
4. Adlbrecht C, Bonderman D, Plass C, et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 2007; 97: 642-649.
5. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
6. Niccoli G, Lanza GA, Shaw S, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006; 27: 1793-1798.
7. Bogoyevitch MA, Glennon PE, Andersson MB, et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994; 269: 1110-1119.
8. Eitel I, Nowak M, Stehl C, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrastenhanced magnetic resonance imaging. Am Heart J 2010; 159: 882-890.
9. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
10. Yip HK, Wu CJ, Chang HW, et al. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005; 127: 1491-1497.
11. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732.
12. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
13. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14367-14372.
14. Iwasa S, Fan J, Miyauchi T, et al. Blockade of endothelin receptors reduces dietinduced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Pathobiology 2001; 69: 1-10.
15. Carbone F, Nencioni A, Mach F, et al. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110: 501-514.
16. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
17. Toffoli MC, Gabra BH, Teixeira CF, et al. Endothelins mediate neutrophil activation, ProMMP-9 release and endothelial cell detachment. Inflammation 2007; 30: 28-37.
18. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006; 114: 1020-1027.
19. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 711-718.
20. Ozdemir R, Parlakpinar H, Polat A, et al. Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 2006; 219: 142-149.
21. Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323-2330.
22. Alberola Aguilar AM, Revert F, Moya A, et al. Intravenous BQ-123 and phosphoramidon reduce ventricular ectopic beats and myocardial infarct size in dogs submitted to coronary occlusion and reperfusion. Gen Pharmacol 2000; 35: 143-147.
23. Maxwell L, Harrison WR, Gavin JB. Endothelin antagonists diminish postischemic microvascular incompetence and necrosis in the heart. Microvasc Res 2000; 59: 204-212.
24. Adlbrecht C, Andreas M, Redwan B, et al. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention 2012; 7: 1386-1395.
25. Reriani M, Raichlin E, Prasad A, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010; 122: 958-966.
26. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008; 52: 522-528.
27. Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 1999; 163: 2816-2820.
28. Peake J, Wilson G, Hordern M, et al. Changes in neutrophil surface receptor expression, degranulation, and respiratory burst activity after moderate-and high-intensity exercise. Journal of applied physiology 2004;97:612-8.
29. Poulsen SH, Host NB, Jensen SE, et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000; 101: 1527-1532.
30. Spratt JC, Goddard J, Patel N, et al. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001; 134: 648-654.
31. Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006; 113: 2398-2405.
32. Verma A, Meris A, Skali H, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imag 2008; 1: 582-591.
33. Pitt B, Latini R, Maggioni AP, et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 2011; 13: 755-764.
34. Lau D, Mollnau H, Eiserich JP, et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005; 102: 431-436.
35. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
36. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
37. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 2001; 37: 137-143.
38. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circulation Res 2001; 89: 969-976.
39. Yoon MH, Reriani M, Mario G, et al. Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol 2013; 168: 1316-1321.
40. Browatzki M, Pfeiffer CA, Schmidt J, et al. Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NFkappaB. Eur J Med Res 2005; 10: 197-201.
41. Babaei S, Picard P, Ravandi A, et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000; 48: 158-167.
42. Morand-Contant M, Anand-Srivastava MB, Couture R. Kinin B1 receptor upregulation by angiotensin II and endothelin-1 in rat vascular smooth muscle cells: receptors and mechanisms. Am J Physiol Heart Circul Physiol 2010; 299: H1625-1232.
43. Fraccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997; 96: 3963-3973.
44. Clozel M, Qiu C, Qiu CS, et al. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002; 39: 142-147.
45. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circulation Res 2005; 97: 125-134.
46. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993; 27: 2125-2129.
47. Nguyen QT, Cernacek P, Sirois MG, et al. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001; 104: 2075-2081.
48. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002; 54: 559-567.
49. Manhenke C, Orn S, von Haehling S, et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013; 166: 729-735.
50. Adlbrecht C, Wurm R, Pezawas T, et al. Effects of endothelin A receptor blockade in patients with ST-elevation acute coronary syndrome-A rhythmologic substudy. Life Sci 2014; Epub ahead of print.